A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Antibodies from the mother passed through placenta protect newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination in third trimester still provides significant protection for infants
Strong evidence from the latest research
The efficacy of the pregnancy RSV vaccine has been confirmed through a comprehensive study conducted across England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing strong and reliable information of the vaccine’s practical effectiveness. The study’s conclusions have been supported by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The scale of this research gives healthcare professionals and parents-to-be with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast highlights the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured actual clinical results rather than laboratory-based settings, providing tangible evidence of how the vaccine performs when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the threats
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests heaving as they attempt to draw adequate oxygen into their damaged lungs. Whilst most newborns improve through palliative treatment, a small but significant proportion perish from respiratory syncytial virus complications each year, making prevention through vaccination a vital health service priority for protecting the youngest and most at-risk people in our communities.
- RSV causes lung inflammation, leading to severe breathing difficulties in infants
- Half of all infants acquire the infection in their first few months of life
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies require serious hospital care for RSV each year
- Small numbers of infants die from RSV related complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the importance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery offers nearly 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The communication from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts launching varied communication campaigns to connect with expectant mothers
- Inconsistencies across regions in immunisation take-up in different parts of England require targeted improvement
- Community health services modifying schemes to suit community needs and circumstances
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness translates into concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against serious illness. Parents no more face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that mark severe RSV infections. The vaccine has substantially transformed the terrain of neonatal respiratory health, offering expectant mothers a active means to protect their youngest infants during those critical early months.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s availability carries deep personal significance. His mother’s support of the jab highlights the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers during their final trimester, changing what was once an predictable seasonal threat into a manageable health risk.